News >

Expert Discusses CMB305 Immunotherapy Regimen in Sarcoma

Danielle Bucco
Published: Monday, Aug 07, 2017

Neeta Somaiah, MD

Neeta Somaiah, MD
Results presented at the 2017 ASCO Annual Meeting showed that CMB305, an immunotherapy regimen that generates and expands anti–NY-ESO-1 T cells, demonstrated a favorable survival rate compared with other approved agents for recurrent soft tissue sarcoma.

, Somaiah, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discussed the efficacy of CMB305 in patients with synovial sarcoma or myxoid/round cell liposarcoma, and its potential as a treatment for other soft tissue sarcomas.

OncLive: Can you provide an overview of this study?

Somaiah: C131 is a phase I study of CMB305 for patients with NY-ESO-1–positive recurrent or metastatic soft tissue sarcoma. CMB305 is a prime boost immunotherapeutic therapy that targets the NY-ESO-1 antigen consisting of LV305, which is a dendritic cell targeting the lentiviral vector. It was also coadministered with G305, which is a potent TLR4 agonist that is given along with the entire NY-ESO protein.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication